Leukemia - Table of Contents alert Volume 26 Issue 3

TABLE OF CONTENTS Volume 26, Issue 3 (March 2012) In this issue Leading Article How to Manage… Spotlight Reviews Reviews Original Articles Letters to the Editor Also new AOP Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement Leukemia SPOTLIGHTS - focusing on topical research in the field of leukemia and allied diseases. Have you read the latest collections? miRNA and Hematopoiesis Guest Editor: Dr. Monique L. den Boer Signaling pathways regulating HSC Guest Editor: Prof. F Staal Explore the full series at www.nature.com/leu/spotlights   Leading Article Top Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial U Platzbecker, M Wermke, J Radke, U Oelschlaegel, F Seltmann, A Kiani, I-M Klut, H Knoth, C Röllig, J Schetelig, B Mohr, X Graehlert, G Ehninger, M Bornhäuser and C Thiede Leukemia 2012 26: 381-389; advance online publication, September 2, 2011; 10.1038/leu.2011.234 Abstract | Full Text How to Manage… Top How to manage lower-risk myelodysplastic syndromes M A Sekeres Leukemia 2012 26: 390-394; advance online publication, September 9, 2011; 10.1038/leu.2011.223 Abstract | Full Text Spotlight Reviews Top SPOTLIGHT ON MIRNA AND HEMATOPOIESIS Epigenetic regulation of miRNA genes in acute leukemia X Agirre, J Á Martínez-Climent, M D Odero and F Prósper Leukemia 2012 26: 395-403; advance online publication, December 6, 2011; 10.1038/leu.2011.344 Abstract | Full Text MicroRNAs in inflammation and immune responses J Contreras and D S Rao Leukemia 2012 26: 404-413; advance online publication, December 20, 2011; 10.1038/leu.2011.356 Abstract | Full Text SPOTLIGHT ON SIGNALING PATHWAYS REGULATING HSC Wnt signaling strength regulates normal hematopoiesis and its deregulation is involved in leukemia development T C Luis, M Ichii, M H Brugman, P Kincade and F J T Staal Leukemia 2012 26: 414-421; advance online publication, December 15, 2011; 10.1038/leu.2011.387 Abstract | Full Text Reviews Top Commentary: does immune suppression increase risk of developing acute myeloid leukemia? R P Gale and G Opelz Leukemia 2012 26: 422-423; advance online publication, August 26, 2011; 10.1038/leu.2011.224 Abstract | Full Text Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome T Krejsgaard, N Odum, C Geisler, M A Wasik and A Woetmann Leukemia 2012 26: 424-432; advance online publication, September 9, 2011; 10.1038/leu.2011.237 Abstract | Full Text Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia E Lengfelder, W-K Hofmann and D Nowak Leukemia 2012 26: 433-442; advance online publication, September 9, 2011; 10.1038/leu.2011.245 Abstract | Full Text Original Articles Top ACUTE LEUKEMIAS MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML B Z Carter, D H Mak, Y Shi, J M Fidler, R Chen, X Ling, W Plunkett and M Andreeff Leukemia 2012 26: 443-450; advance online publication, September 9, 2011; 10.1038/leu.2011.246 Abstract | Full Text (+)α-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo G A S dos Santos, R S Abreu e Lima, C R Pestana, A S G Lima, P S Scheucher, C H Thomé, H L Gimenes-Teixeira, B A A Santana-Lemos, A R Lucena-Araujo, F P Rodrigues, R Nasr, S A Uyemura, R P Falcão, H de Thé, P P Pandolfi, C Curti and E M Rego Leukemia 2012 26: 451-460; advance online publication, August 26, 2011; 10.1038/leu.2011.216 Abstract | Full Text Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: a matched-pair analysis K Ishiyama, A Takami, Y Kanda, S Nakao, M Hidaka, T Maeda, T Naoe, S Taniguchi, K Kawa, T Nagamura, Y Atsuta and H Sakamaki Leukemia 2012 26: 461-464; advance online publication, August 26, 2011; 10.1038/leu.2011.229 Abstract | Full Text CHRONIC MYELOPROLIFERATIVE NEOPLASIAS NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR–ABL-positive mice C I-U Chen, S Koschmieder, L Kerstiens, M Schemionek, B Altvater, S Pscherer, J Gerss, H T Maecker, W E Berdel, H Juergens, P P Lee and C Rossig Leukemia 2012 26: 465-474; advance online publication, September 9, 2011; 10.1038/leu.2011.239 Abstract | Full Text IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F A Tefferi, T Jimma, N H Sulai, T L Lasho, C M Finke, R A Knudson, R F McClure and A Pardanani Leukemia 2012 26: 475-480; advance online publication, September 13, 2011; 10.1038/leu.2011.253 Abstract | Full Text The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity M M Reddy, M S Fernandes, A Deshpande, E Weisberg, H V Inguilizian, O Abdel-Wahab, A L Kung, R L Levine, J D Griffin and M Sattler Leukemia 2012 26: 481-489; advance online publication, August 23, 2011; 10.1038/leu.2011.225 Abstract | Full Text Release of intracellular calcium primes chronic myeloid leukaemia cells for tyrosine kinase inhibitor-induced apoptosis S L Forchap, M Pirmohamed and R E Clark Leukemia 2012 26: 490-498; advance online publication, September 2, 2011; 10.1038/leu.2011.231 Abstract | Full Text CHRONIC LYMPHOCYTIC LEUKEMIA Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays M Ciccone, C Agostinelli, G M Rigolin, P P Piccaluga, F Cavazzini, S Righi, M T Sista, O Sofritti, L Rizzotto, E Sabattini, G Fioritoni, S Falorio, C Stelitano, A Olivieri, I Attolico, M Brugiatelli, P L Zinzani, E Saccenti, D Capello, M Negrini, A Cuneo and S Pileri Leukemia 2012 26: 499-508; advance online publication, September 23, 2011; 10.1038/leu.2011.247 Abstract | Full Text STEM CELLS Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation S Breuer, S Preuner, G Fritsch, H Daxberger, M Koenig, U Poetschger, A Lawitschka, C Peters, G Mann, T Lion and S Matthes-Martin Leukemia 2012 26: 509-519; advance online publication, September 16, 2011; 10.1038/leu.2011.244 Abstract | Full Text LYMPHOMA Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect A Dodero, F Spina, F Narni, F Patriarca, I Cavattoni, F Benedetti, F Ciceri, D Baronciani, R Scimè, E Pogliani, A Rambaldi, F Bonifazi, S Dalto, B Bruno and P Corradini Leukemia 2012 26: 520-526; advance online publication, September 9, 2011; 10.1038/leu.2011.240 Abstract | Full Text Letters to the Editor Top Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission W-C Chou, K-Y Peng, W-C Lei, B-S Ko, W Tsay, C-H Kuo and H-F Tien Leukemia 2012 26: 527-529; advance online publication, August 16, 2011; 10.1038/leu.2011.215 Full Text WT1 peptide vaccination following allogeneic stem cell transplantation in pediatric leukemic patients with high risk for relapse: successful maintenance of durable remission Y Hashii, E Sato-Miyashita, R Matsumura, S Kusuki, H Yoshida, H Ohta, N Hosen, A Tsuboi, Y Oji, Y Oka, H Sugiyama and K Ozono Leukemia 2012 26: 530-532; advance online publication, August 26, 2011; 10.1038/leu.2011.226 Full Text Functional role of BAALC in leukemogenesis M Heuser, T Berg, F Kuchenbauer, C K Lai, G Park, S Fung, G Lin, M Leung, J Krauter, A Ganser and R K Humphries Leukemia 2012 26: 532-536; advance online publication, August 26, 2011; 10.1038/leu.2011.228 Full Text NIH-defined graft-versus-host disease after reduced intensity or myeloablative conditioning in patients with acute myeloid leukemia T H Terwey, A Vega-Ruiz, P G Hemmati, P Martus, E Dietz, P le Coutre, G Massenkeil, B Dörken and R Arnold Leukemia 2012 26: 536-542; advance online publication, August 26, 2011; 10.1038/leu.2011.230 Full Text SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts V Visconte, H Makishima, A Jankowska, H Szpurka, F Traina, A Jerez, C O'Keefe, H J Rogers, M A Sekeres, J P Maciejewski and R V Tiu Leukemia 2012 26: 542-545; advance online publication, September 2, 2011; 10.1038/leu.2011.232 Full Text Action of novel CD37 antibodies on chronic lymphocytic leukemia cells G Krause, M Patz, P Isaeva, M Wigger, I Baki, V Vondey, S Kerwien, M Kuckertz, R Brinker, J Claasen, L P Frenzel, C-M Wendtner, K-H Heider and M Hallek Leukemia 2012 26: 546-549; advance online publication, September 2, 2011; 10.1038/leu.2011.233 Full Text Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities C Vicente, I Vazquez, A Conchillo, M A García-Sánchez, N Marcotegui, O Fuster, M González, M J Calasanz, I Lahortiga and M D Odero Leukemia 2012 26: 550-554; advance online publication, September 9, 2011; 10.1038/leu.2011.235 Full Text The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations E Tiacci, A Spanhol-Rosseto, M P Martelli, L Pasqualucci, H Quentmeier, V Grossmann, H G Drexler and B Falini Leukemia 2012 26: 554-557; advance online publication, September 9, 2011; 10.1038/leu.2011.238 Full Text The surface molecule signature of primary human acute myeloid leukemia (AML) cells is highly associated with NPM1 mutation status G Tsykunova, H Reikvam, R Hovland and Ø Bruserud Leukemia 2012 26: 557-559; advance online publication, September 9, 2011; 10.1038/leu.2011.243 Full Text High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis E Launay, C Pangault, P Bertrand, F Jardin, T Lamy, H Tilly, K Tarte, C Bastard and T Fest Leukemia 2012 26: 559-562; advance online publication, September 23, 2011; 10.1038/leu.2011.266 Full Text Advertisement Nature Immunology presents a webcast series on Current Controversies Webcasts now available free on demand on the following topics: Lineage Differentiation HIV Vaccines Human Immunology Sponsored by:   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.